CD52 and acute myeloid leukemia: Interestingly, a previous study reported that the administration of alemtuzumab in NOD SCID gamma (NSG) mice significantly suppressed the engraftment of AML patient-derived CD52-positive leukemia cells with the FLT3-ITD mutation, while not suppressing engraftment of leukemia cells lacking the FLT3-ITD mutation22.